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Rethinking metabotropic glutamate receptor 5 pathological findings in
psychiatric disorders: implications for the future of novel therapeutics
Abstract
Background Pharmacological modulation of metabotropic glutamate receptor 5 (mGluR5) is of marked
interest as a novel therapeutic mechanism to treat schizophrenia and major depression. However, the
status of mGluR5 in the pathophysiology of these disorders remains unknown. Discussion The majority of
studies in the schizophrenia post-mortem brain indicate that total mGluR5 expression is unaltered.
However, close examination of the literature suggests that these findings are superficial, and in actuality,
a number of critical factors have not yet been considered; alterations may be highly dependent on brain
region, neuronal population or molecular organisation in specific cellular compartments. A number of
genetic knockout studies (mGluR5, Norbin, Homer1 etc.) continue to lend support to a role of mGluR5 in
the pathology of schizophrenia, providing impetus to explore the regulation of mGluR5 beyond total
mGluR5 protein and mRNA levels. With regards to major depression, preliminary evidence to date shows
a reduction in total mGluR5 protein and mRNA levels; however, as in schizophrenia, there are no studies
examining mGluR5 function or regulation in the pathological state. A comprehensive understanding of
mGluR5 regulation in major depression, particularly in comparison to schizophrenia, is crucial as this has
extensive implications for mGluR5 targeting novel therapeutics, especially considering that opposing
modulation of mGluR5 is of therapeutic interest for these two disorders. Summary Despite the
complexities, examinations of post-mortem human brain provide valuable insights into the pathologies of
these inherently human disorders. It is important, especially with regards to the identification of novel
therapeutic drug targets, to have an in depth understanding of the pathophysiologies of these disorders.
We posit that brain region- and cell type-specific alterations exist in mGluR5 in schizophrenia and
depression, with evidence pointing towards altered regulation of this receptor in psychiatric pathology. We
consider the implications of these alterations, as well as the distinction between schizophrenia and
depression, in the context of novel mGluR5 based therapeutics.
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Abstract
Background: Pharmacological modulation of metabotropic glutamate receptor 5 (mGluR5) is of marked interest as
a novel therapeutic mechanism to treat schizophrenia and major depression. However, the status of mGluR5 in the
pathophysiology of these disorders remains unknown.
Discussion: The majority of studies in the schizophrenia post-mortem brain indicate that total mGluR5 expression
is unaltered. However, close examination of the literature suggests that these findings are superficial, and in
actuality, a number of critical factors have not yet been considered; alterations may be highly dependent on brain
region, neuronal population or molecular organisation in specific cellular compartments. A number of genetic
knockout studies (mGluR5, Norbin, Homer1 etc.) continue to lend support to a role of mGluR5 in the pathology of
schizophrenia, providing impetus to explore the regulation of mGluR5 beyond total mGluR5 protein and mRNA
levels. With regards to major depression, preliminary evidence to date shows a reduction in total mGluR5 protein
and mRNA levels; however, as in schizophrenia, there are no studies examining mGluR5 function or regulation in
the pathological state. A comprehensive understanding of mGluR5 regulation in major depression, particularly in
comparison to schizophrenia, is crucial as this has extensive implications for mGluR5 targeting novel therapeutics,
especially considering that opposing modulation of mGluR5 is of therapeutic interest for these two disorders.
Summary: Despite the complexities, examinations of post-mortem human brain provide valuable insights into the
pathologies of these inherently human disorders. It is important, especially with regards to the identification of novel
therapeutic drug targets, to have an in depth understanding of the pathophysiologies of these disorders. We posit that
brain region- and cell type-specific alterations exist in mGluR5 in schizophrenia and depression, with evidence pointing
towards altered regulation of this receptor in psychiatric pathology. We consider the implications of these alterations, as
well as the distinction between schizophrenia and depression, in the context of novel mGluR5 based therapeutics.
Keywords: Metabotropic glutamate receptor, mGlu, mGluR5, GRM, Schizophrenia, Depression, Post-mortem human
brain, Novel antipsychotic, Novel antidepressant, Glutamate

Background
Metabotropic glutamate receptor subtype 5 (mGluR5) is an
exciting novel drug target for the treatment of psychiatric
disorders including schizophrenia and major depression
[1,2]. While the monoaminergic systems (e.g. dopamine,
serotonin, norepinephrine) are the main therapeutic targets
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of current drugs used to treat schizophrenia and major depression, evidence suggests that the glutamatergic system
and the N-methyl-D-aspartate receptor (NMDAR) in particular, play a key role in the underlying pathophysiology of
these disorders, at least in a subset of patients [3-6]. Targeting the glutamatergic NMDAR is therefore considered a
novel treatment strategy for these disorders. Accordingly,
NMDAR agonists such as d-serine show therapeutic potential for the treatment of schizophrenia [7], whilst the
NMDAR antagonist ketamine shows rapid antidepressant
effects in patients with treatment-resistant depression [8,9].
In both cases however, NMDAR-targeting drugs are
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confounded, specifically by high dose requirements and the
associated risk of excitotoxicity in the case of agonists [7],
and psychotomimetic effects, addictive properties and cognitive decline in the case of antagonists [10-13]. As a result
of these confounds, the metabotropic glutamate receptors
have been identified as a possible avenue to regulate glutamatergic transmission, while minimising the unwanted effects of targeting the NMDAR directly [2,14]. mGluR5 is of
particular interest as it shares a structural and functional
link with the NMDAR, but unlike the NMDAR it is localised in more selective brain regions where it fine-tunes glutamatergic transmission [1].
mGluR5 positive allosteric modulators (PAMs) upregulate NMDAR function [15], whilst mGluR5 antagonists
and negative allosteric modulators (NAMs) downregulate
NMDAR activity [16]. These agents therefore have the potential to treat NMDAR hypofunction and hyperfunction
states associated with schizophrenia and major depression
respectively. In spite of this exciting possibility, the success
of novel mGluR5-based therapeutics is dependent on the
status of mGluR5 in these disorders. Conflicting data between human pathophysiological studies, genetic studies
and animal studies make it unclear whether mGluR5 is indeed altered in these pathologies and what implications
this has for novel mGluR5 based therapeutics.

Discussion
Neuropathological findings and considerations
Protein studies

Post-mortem analyses of human brain tissue from psychiatric patients provide valuable insight into the potential
pathophysiology of these disorders. Often however, findings in post-mortem human brain are inconsistent with
findings in more mechanistic studies such as animal- and/
or cell- based studies, highlighting the complexities of
these psychopathologies. We have recently reviewed the literature with regards to examination of mGluR5 in schizophrenia [1]. Three out of four studies examining mGluR5
protein in post-mortem brain samples from schizophrenia
subjects (number of subjects ranging from 9 to 37) identified no change in mGluR5 protein (monomer) levels in the
prefrontal cortex (PFC), specifically Brodmann’s areas (BA)
9, 10, 11, 32 and 46 as well as the caudate, putamen and
nucleus accumbens [17-19]. In contrast to these findings,
Fatemi and colleagues [20] recently reported a large reduction in mGluR5 protein (monomer) levels in the PFC
(BA9) and lateral cerebellum of subjects with schizophrenia compared to controls (n = 15-20). Collectively, these
findings raise the strong probability that alterations to
mGluR5 in schizophrenia are brain region-specific and
possibly cohort specific. This reinforces the importance of
replication of findings in adjacent brain regions and independent cohorts and raises the notion that it is likely that
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mGluR5-based therapeutics will mediate region-specific effects as well as individual-specific effects depending on the
underlying neuropathology.
In major depression, mGluR5 monomer protein
levels have been reported to be reduced in the lateral
cerebellum [20] and prefrontal cortex (BA10) [21]
using two different cohorts (n = 15). While this might
suggest less heterogeneity of changes in this disorder,
the findings should be deemed as preliminary until
additional brain regions are examined and findings further replicated in independent cohorts. An important
way forward for both schizophrenia and major depression will be to identify these cohort specific changes in
mGluR5, as well as other markers, in living patients.
The detection of peripheral biomarkers, such as singlenucleotide polymorphisms, that have associations with
symptoms and brain pathology (for example, see
[5,22]), may pave the way for an individualised treatment approach.
A fundamental issue confounding the interpretation
of these aforementioned immunoblot studies is that the
majority have focused on mGluR5 in the monomer form.
Mature functional mGluR5s exist in a disulphide-linked
dimer complex [23,24] and can only be activated by agonists when in this dimer form [23]. Thus, alterations in
monomers alone may not have functional significance.
While one study reported no change in mGluR5 dimer
levels in the PFC (BA9) and lateral cerebellum in schizophrenia and major depression [20], the use of reducing
conditions (5% β-mercaptoethanol, which breaks disulphide links) would have interfered with the dimerized status of mGluR5. It is therefore unlikely that total dimers
were indeed measured and rather these measures were an
artefact of the experimental procedure, whereby the ratio
of monomers and dimers is reflective of the amount of reducing agent used rather than a physiological indication.
There are no reported investigations of mGluR5 dimer
measures in non-reducing conditions in schizophrenia or
depression, however altered dimerization of another
mGluR, mGluR3, has been found in the PFC of schizophrenia subjects [25]. It is crucial to take these experimental variables into account for future mGluR5 immunoblot
studies, and to determine whether dimer assembly is disrupted in these neuropathologies, as this would render
mGluR5 present, but inactive, thereby having implications for the novel class of mGluR5-targeting therapeutics.
While mGluR5 monomers are considered non-functional
as they cannot be activated by agonists, a recent report
suggests that mGluR5 monomers are able to couple to
G-proteins upon activation with a PAM [23]. However
more research is required to determine if mGluR5 dimers are altered in these psychiatric pathologies and
what impact this has on the effectiveness of mGluR5
allosteric agents [26].
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Receptor binding studies

Another valuable approach to understanding mGluR5 in
psychiatric pathology and its potential as a therapeutic target is the use of radiolabeled drugs that target the therapeutic binding site of interest. We have recently reported
no change in binding to the MPEP site of mGluR5 in the
post-mortem dorsolateral PFC of schizophrenia patients
[17]. We have also since found unaltered mGluR5 binding
in the anterior cingulate cortex of schizophrenia, major
depression and bipolar subjects in the Stanley Neuropathology Consortium (unpublished observations). Considering many novel mGluR5 drugs target the MPEP site, our
findings suggest that this binding site is accessible in these
disorders, at least in the dorsolateral PFC and anterior cingulate cortex. While these are the only studies to have examined mGluR5 binding in schizophrenia, Deschwanden
et al. [21] reported region-specific reductions in [11C]
ABP688 in-vivo binding to the MPEP site in the PFC, insula, and parts of the parietal and temporal cortices in living patients with depression. These alterations were
associated with depressive symptom severity. Considering
Deschwanden and colleagues also reported reductions in
mGluR5 protein in the PFC in major depression (in a separate post-mortem cohort) [21], it is possible that these reductions in binding and protein represent a reduction in
overall mGluR5 numbers in the PFC in depression. Notably, in line with our observations, no significant change
in binding was reported in the anterior cingulate cortex
[21]. The assessment of binding specifically to membrane
bound mGluR5 and the affinity of novel mGluR5 targeting
drugs to binding sites in the brains of patients with schizophrenia and depression will aid in understanding the potential of these drugs for the treatment of psychiatric
disorders. While assessment of the MPEP binding site offers insight into the binding kinetics of mGluR5 drugs that
target this site, it must be noted that there is a family of
mGluR5 allosteric modulators that do not bind to this site
[27-29], and currently there are no radioligands available
to directly assess the density and affinity of these nonMPEP sites.
mRNA studies

Although mRNA analyses do not directly equate to functional protein expression [30], examination of mRNA offers several advantages. Firstly, it allows for analyses of
amino acid sequences that are highly specific to the molecule or isoform of interest. Secondly, to gain an understanding of underlying mechanisms of any changes in
protein expression (for example whether they may be the
result of changes in rate of synthesis), examination of
mRNA expression is essential. Most recently, it was reported that there was no change in mGluR5(pan) mRNA
in the PFC(BA9), together with a reduction in mGluR5
(pan) mRNA in the lateral cerebellum in schizophrenia
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[20]. This same study found reduced mGluR5 protein in
both the cerebellum and PFC, indicating possible deficits in mGluR5 synthesis in the cerebellum, but posttranscriptional modifications in the PFC. Consistent with
this, four previous studies found no change in mGluR5
mRNA in the PFC (BA9/10), as well as the thalamus or
hippocampus in schizophrenia [31-34]. One study did however report an increase in mGluR5 mRNA expression in
the PFC (BA11; n = 7-10), which was specific to cortical
layer III [34], a layer concerned with cortico-cortical projections and that is particularly implicated in schizophrenia
pathophysiology [35]. It should therefore be considered that
alterations in mGluR5 mRNA are not only brain regionspecific, but may also exist specifically in selective neuronal
populations in the diseased brain, and analyses of total
neuron populations may therefore conceal pathological alterations. With regards to major depression, preliminary
studies suggest concordant reductions in mRNA and protein in post-mortem brain samples. Fatemi et al. [20] recently reported a reduction in mGluR5(pan) mRNA in the
lateral cerebellum in major depression, consistent with their
finding of reduced mGluR5 protein in this same region.
This suggests that a reduction in mGluR5 production may
occur, at least in this brain region, in major depression. To
our knowledge, there are no other studies examining
mGluR5 mRNA in major depression to shed light on the
mechanism and extent of mGluR5 alterations in this
disorder.
Further considerations

When approaching mGluR5 post-mortem findings in the
context of future therapies, there has been minimal consideration of the structural complexity of this receptor. To
date, mGluR5a, b, and d isoforms have been identified.
These isoforms differ in their developmental profile, brain
region localisation, and length of their c-terminus [1,36,37].
While mGluR5a and mGluR5b share similar pharmacological profiles they have opposing functions, at least in
development, where mGluR5a inhibits and mGluR5b promotes neurite outgrowth [37]. Compared to mGluR5a and
b, the mGluR5d isoform has increased sensitivity to desensitisation and has a shorter intracellular c-terminus by a significant 267 amino acids [36]; consequently mGluR5d has
less interaction with scaffolding molecules that modulate
the mGluR5/NMDAR complex (e.g. Homer), and other endogenous molecules that ensure its trafficking and cell surface localisation. This is important to consider, especially in
the context of schizophrenia where the majority of studies
indicate no change in overall mGluR5 levels; there may
in reality be altered regulation, trafficking or recycling of
mGluR5 or altered receptor-receptor interactions. For
example, Homer, Norbin (neurochondrin) and Tamalin
(GRASP1) act as chaperones to increase cell surface localisation of mGluR5. Homer and Norbin knockout mice
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show a schizophrenia-like behavioural phenotype [38,39],
suggesting there may be deficits in membrane-bound localisation of mGluR5 in schizophrenia. Supporting this hypothesis, the mGluR5 GRM5 gene has recently been
suggested as one of the top candidate genes for schizophrenia vulnerability [40,41], with exome sequencing of multiplex pedigrees reporting disruption to the mGluR5/Tamalin
association [40]. Consistent with this notion, mGluR5
knockout mice and mice treated with mGluR5 antagonists also demonstrate schizophrenia-like behaviours
(and interestingly antidepressant behaviours, as discussed below) [1,42]. While these mGluR5 regulatory
molecules have not been considered in the context of
depression, Homer1 has been implicated in the aetiology
of major depression through a genome wide association
study [43], suggesting possible disruptions to mGluR5
trafficking and/or mGluR5/NMDAR interactions in this
disorder also.
Opposing glutamatergic dysregulation in schizophrenia
and depression: Implications for novel mGluR5 therapeutics

mGluR5 PAMs have shown promise in preclinical rodent
models for the treatment of schizophrenia [1]. mGluR5
PAMs, such as CDPPB and more recently VU0364289,
demonstrated the ability to attenuate phencyclidine and
amphetamine-induced hyperlocomotion, social interaction
deficits, prepulse inhibition deficits and importantly, cognitive deficits (which are largely untreated by current antipsychotics) [1,44]. While the development of mGluR5
PAMs have faced issues with regards to solubility and oral
bioavailability, a new generation of PAMs appear to have
overcome these issues [45-47]. In contrast, mGluR5
NAMs, including MPEP and MTEP, have shown antidepressant properties in rodent models, including reduced
immobility time in forced swim and tail suspension tests,
key tests of antidepressant efficacy in rodent models
[48-50]. However, some mGluR5 NAMs have also shown
the ability to produce psychotomimetic side effects in rodent models, similar to the NMDAR antagonist ketamine
[51]. More recent drug design has resulted in the development of mGluR5 NAMs that appear to lack this psychotomimetic property [47].
While the glutamatergic system is implicated in the
pathophysiologies of both schizophrenia and major depression, the use of mGluR5 PAMs for the treatment of
schizophrenia and NAMs for the treatment of depression,
suggests opposing disturbances of the glutamatergic system in these disorders. Although the data for mGluR5 in
the schizophrenia brain is conflicting across studies [1,20]
(possibly as a result of region-specific pathology), a decline
in mGluR5 in depression has now been replicated in three
cohorts [20,21]. However, negative modulation of mGluR5
has been reported to have therapeutic efficacy in preclinical (rodent) models of depression [9,52]. In addition,
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NMDAR antagonists, such as ketamine, demonstrate antidepressant properties in treatment resistant patients [10].
From the outset, the use of these therapies might indicate
a hyperglutamatergic state or specific NMDAR hyperfunction in depression, suggesting that the mGluR5 reduction
seen in patients with depression represents an endogenous
compensatory response, and that the use of mGluR5
NAMs may act to further assist this mGluR5 downregulation. This is supported by findings of increased glutamate
levels in the brains of some patients with depression
[4,53-55]. As the results of clinical trials for mGluR5
NAMs in depression are not yet available, the therapeutic
effects remain to be seen. It is likely that the incorporation
of mGluR5-based therapeutics will be individualized depending on symptom profile and individual pathology.
The issues raised here are not limited to schizophrenia
and major depression. Glutamatergic dysfunction is also
implicated in other neuropsychiatric disorders including
anxiety and Fragile X Syndrome. mGluR5 NAMs prevent
behavioural phenotypes in animal models of these disorders [56-58]. mGluR5 NAMs including Fenobam and
AFQ056 have progressed to clinical trials where they
showed therapeutic effects for the treatment of anxiety
and Fragile X Syndrome [59-61]. However there were reports of psychotomimetic effects following chronic treatment in some patients [59]. In addition, a recent study
provides evidence that patient response to these mGluR5
NAMs may depend on individual pathophysiology [61].
This demonstrates, despite some limitations which are being considered in current drug design [62], that this class
of drugs has the potential to progress into clinical therapeutics. mGluR5 PAMs on the other hand are yet to reach
clinical trials.

Summary
We suggest that, despite post-mortem studies largely
indicating no involvement of mGluR5 in the pathology
of schizophrenia, and preliminary evidence suggesting
it is down-regulated in major depression, that there is
evidence in both pathologies of altered regulation of
this receptor, possibly in a brain region- and cell typespecific manner. In spite of the rapid movement to develop mGluR5 pharmaceutical modulators, there has
been very limited investigation into the function and
regulation of mGluR5 at the genetic, mRNA and protein levels in the pathological post-mortem human and
animal paradigms [63]. Only with this knowledge will
we be able to tailor novel therapeutics to treat these
diseases. It is likely that mGluR5-based therapeutics
will be much individualised depending on symptom
profile. Pharmacogenomics or peripheral biomarkers
may help to identify the patients that would suit
mGluR5-modulation as a therapy option.
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